Grifols, S.A. (GIFLF)
| Previous close | 12.81 |
| Open | 12.81 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 12.81 - 12.81 |
| 52-week range | 9.99 - 15.34 |
| Volume | |
| Avg. volume | 191 |
| Market cap | 10.579B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | 320.25 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 03 June 2021 |
| 1y target est | N/A |
- PR Newswire
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced the launch of its new Grifols sCD38 solution, the industry's first-ever soluble recombinant protein designed to block anti-CD38 antibodies in multiple myeloma patients receiving daratumumab therapy, ensuring quick and accurate blood transfusion tests that are critical for proper treatment.
- GlobeNewswire
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human) intravenousThis first in-human subcutaneous approach to treating alpha1-antitrypsin deficiency, if proven successful in clinical trials, could give patients the convenience and flexibility to administer their medication from home BARCELONA, Spain, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, M
- GlobeNewswire
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023
Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA) GigaGen anticipates trial initiation in 2024 GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade SAN CARLOS, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing tran
